Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: Acute toxicity and preliminary response

Cancer

Volumn 115, Issue 15, 2009, Pages 3571-3580

  Kao, Johnny ^a,b   Packer, Stuart ^a   Ha, Linh Vu ^a   Schwartz, Myron E ^a   Sung, Max W ^a   Stock, Richard G ^a   Lo, Yeh Chi ^a   Huang, Delphine ^a   Chen, Shu Hsia ^a   Cesaretti, Jamie A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Cancer; Image guided radiotherapy; Oligometastases; Sunitinib

Indexed keywords

SUNITINIB;

ADULT; AGED; ANEMIA; ARTICLE; BONE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LIVER; LIVER FUNCTION TEST; LUNG; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RECTUM HEMORRHAGE; SIDE EFFECT; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PATIENT COMPLIANCE; PYRROLES; RADIATION DOSAGE;

EID: 68149170060     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24412     Document Type: Article

References (31)

1. Bailar JC 3rd, Gornik HL. Cancer undefeated. N Engl J Med. 1997;336:1569-1574.
2. DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia and London: Lippincott Williams & Wilkins; 2005.
3. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938-946.
4. Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999;229:602-610.
5. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8-10.
6. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
8. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040-2048.
9. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
10. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
11. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
12. Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
13. Mehta N, Mauer AM, Hellman S, et al. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004;25:1677-1683.
14. Gonzalez-Garcia I, Sole RV, Costa J. Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci USA. 2002;99:13085-13089.
15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
16. Tannock IF. Conventional cancer therapy: promise broken or promise delayed? Lancet. 1998;351(suppl 2):SII9-SII 16.
17. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 1998;394:287-291.
18. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003;63:4009-4016.
19. Kao J, Mundt AJ. Metastatic and Recurrent Tumors. In: Mundt AJ, Roeske JC, eds. Intensity Modulated Radiation Therapy: A Clinical Perspective. Hamilton: BC Decker; 2005:593-598.
20. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007;25:947-952.
21. Milano MT, Katz AW, Muhs AG, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2008;112:650-658.
22. Milano MT, Constine LS, Okunieff P. Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiat Oncol. 2008;3:36.
23. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
24. Salama JK, Chmura SJ, Mehta N, et al. An initial report of a radiation dose-escalation trial in patients with 1 to 5 sites of metastatic disease. Clin Cancer Res. 2008;14:5255-529.
25. Timmerman RD, Forster KM, Chinsoo Cho L. Extracranial stereotactic radiation delivery. Semin Radiat Oncol. 2005;15:202-207.
26. Gerszten PC, Ozhasoglu C, Burton SA, et al. CyberKnife frameless stereotactic radiosurgery for spinal lesions: clinical experience in 125 cases. Neurosurgery. 2004;55:89-98;discussion 98-9.
27. Herfarth KK, Debus J, Lohr F, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19:164-170.
28. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-1338.
29. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26:1810-1816.
30. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25-35.
31. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127-132.